On Dec. 13, the U.S. Supreme Court granted certiorari in the FDA v. Alliance for Hippocratic Medicine and will hear oral arguments in the case this term. In August, the 5th U.S. Circuit Court of Appeals ruled that important safety precautions surrounding the use of the chemical abortion drug, mifepristone, must be reinstated, drastically restricting the availability of this harmful drug.
The 5th Circuit’s decision did not immediately go into effect due to an earlier ruling from the Supreme Court which temporarily allows mifepristone to remain on the market with no restrictions while litigation proceeds. Now, the Supreme Court will weigh in on the merits of this case and make a final decision on upholding or discarding these precautions.
RELATED: Check out other stories on this and other similar issues here.
If the court upholds the 5th Circuit’s ruling, it will reinstate key safety measures such as:
- limiting the use of the drug to the first 7 weeks of pregnancy,
- ending mail-order chemical abortions,
- and requiring in-person medical visits prior to the drugs being prescribed.
Chemical abortions account for a majority of all abortions in the U.S., particularly in states where abortion has been restricted or banned following the Dobbs decision.
What is this case about?
In November 2022, Alliance Defending Freedom filed suit against the FDA on behalf of four pro-life medical groups. The suit claims that the FDA “failed America’s women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States. And it has continued to fail them by repeatedly removing even the most basic precautionary requirements associated with their use.”
These pro-life groups argue that the FDA was wrong to grant the drug mifepristone fast-tracked approval back in 2000. The complaint continues:
The only way the FDA could have approved chemical abortion drugs was to use its accelerated drug approval authority, necessitating the FDA to call pregnancy an “illness” and argue that these dangerous drugs provide a “meaningful therapeutic benefit” over existing treatments.
But pregnancy is not an illness, nor do chemical abortion drugs provide a therapeutic benefit over surgical abortion. In asserting these transparently false conclusions, the FDA exceeded its regulatory authority to approve the drugs.
Currently, 1 in 5 women who take the drug will experience complications that require further medical attention. The case argues that the disposal of original safety precautions that accompanied the drug’s initial approval have led to increased danger to the women and girls who take mifepristone.
In 2016, the FDA:
- Expanded the availability of chemical abortion drugs from 7 weeks of pregnancy up to 10 weeks of pregnancy,
- Changed the dosing regimen,
- Reduced the number of in-person doctor visits from three to one,
- Expanded who could prescribe and administer chemical abortion drugs beyond medical doctors,
- And eliminated the requirement for prescribers to report non-fatal complications from chemical abortion drugs.
Then, in 2021, the FDA removed the requirement of in-person dispensing, allowing for abortion drugs to be accessed through the mail and telemedicine without a woman ever seeing a doctor in-person.
At this point in litigation, the court is no longer considering the initial approval of mifepristone but has narrowed its consideration to the removal and potential reinstatement of these vital safety precautions.
What happens next?
This case will now be scheduled for oral argument, likely in early 2024, with a decision expected in June. The court’s previous 7–2 ruling in April was narrowly focused on the availability of mifepristone as litigation proceeded and did not look at the broader merits of the case. It should not necessarily be viewed as a predictor of how the court will rule.
Southern Baptists care about the sanctity of life and dignity of all people, including the preborn. We also care about the health, safety and welfare of women who have experienced harmful and serious medical complications from these drugs at the hands of the predatory abortion industry. The ERLC is currently evaluating opportunities to file an amicus brief, making these arguments before the court.
If the court upholds this decision from the 5th Circuit, more preborn lives will be saved and more women will be protected from the dangers intrinsic to chemical abortions. We will continue to work toward a day when chemical abortions are no more, and we pray that the Supreme Court will take this step forward as we work to build a true culture of life and to protect the health, safety, and welfare of women and girls.
EDITOR’S NOTE — This story was written by Hannah Daniel and originally published by the Ethics & Religious Liberty Commission.
